易明医药：9月19日召开董事会会议

Group 1 - The core point of the article is that Yiming Pharmaceutical announced the convening of its fourth board meeting and discussed the appointment of the internal audit director [1] - For the first half of 2025, Yiming Pharmaceutical's revenue composition shows that drug sales accounted for 99.71%, other revenues accounted for 0.58%, and drug promotion services accounted for -0.29% [1] - As of the report date, Yiming Pharmaceutical has a market capitalization of 3.8 billion yuan [1] Group 2 - The article also mentions that the parent company of the brand "Ancestor Bird" is facing challenges, with the new president of Greater China having been in office for just over two months and praised for his professional capabilities [1]